🚧 The status quo of biological model discovery, development, and biomanufacturing is blocking progress on some of humanity’s greatest biomedical breakthroughs.
At iOrganBio, we’re re-designing cell model discovery and manufacturing from the ground up, leveraging modern automation and machine learning as fundamental components of our system. Using rapid turnaround scRNA-seq, we are able to digitize cell state and automatically guide stem cell differentiation towards bioequivalency using in vivo cell states as a blueprint.
Our platform unlocks the next stage of biotechnological development, treating cells as the complex and dynamic systems that we’ve always known them to be. Join us as we transform the way we use cells to cure disease and forge progress using The Right Cells, Consistently, At Scale.
🌐 Learn more about our tech at https://t.co/GkpfmszecN
✉️ To start a collaboration with iOB, email [email protected]
“We are excited to partner with iORGANBIO in contributing to greater efficiency in drug discovery and advancements in cell therapy and regenerative medicine. This new partnership will directly support Mitsui Chemicals’ aim to create new solutions that support life, health and enriched lifestyles,” said Shunsuke Fujii, PhD, General Manager at Mitsui Chemicals.
Following last week’s news, we’re excited to share more about our collaboration with Mitsui Chemicals.
Mitsui Chemicals brings more than a century of materials science and innovative chemical formulations, including its InnoCell™ cell culture plates. Their highly oxygen-permeable design supports healthier, longer-lasting cultures and more uniform 3D tissues, including iPSC-derived organoids.
iOrganBio brings an integrated Physical AI platform built to develop and manufacture consistent human cells at scale. CellHorizon defines the target cell state, while CellDiscovery rapidly explores the experimental design space to find the conditions that reach it. CellTelemetry digitizes every manufactured cell, giving our adaptive manufacturing platform, CellForge, the real-time insight it needs to deliver consistent cells, batch after batch.
Together, we aim to:
📷 Enable cell types and complex organoids that have been difficult to manufacture
📷 Control culture conditions to improve the quality and consistency of human cells and organoids
📷 Explore new drug discovery technologies, including efficacy and safety testing, that could complement or replace animal testing
📷 Develop new materials and methods to dynamically interact with cells and precisely guide their behavior
Read the full press release here: https://t.co/RkdIwnQQAn
Excited to present three posters at the #ISSCR Disease Modeling & Drug Discovery Symposium, Dec 16–18 in San Diego! Come find us at the poster sessions to see how CellForge™ and CellDiscovery™ are making stem-cell manufacturing adaptive.
We’re honored to announce an investment from Mitsui Chemicals Group through 321Catalyst Ventures!
In our new collaboration, we’ll pair InnoCell™ plates with our AI-driven, closed-loop platform to make more consistent human cells and organoids for drug screening.
Timing couldn’t be better: in September, the FDA made clear animal studies aren’t the only path to safety data before human trials. Reliable human cell models will be key to what comes next.
Thank you to the Mitsui Chemicals and 321Catalyst teams for their support!
🚀 The launch of NIH’s Office of Research Innovation, Validation, and Application (ORIVA) is a major milestone for the non-animal methods (NAMs) ecosystem.
By coordinating NIH-wide efforts to develop, validate, and scale human-based research approaches—and by supporting funding, training, and regulatory translation—ORIVA signals a meaningful shift toward models that are more human-relevant, translatable, and fit for modern biomedical research.
At @iOrganBio, we see this as strong momentum for the future of precision cell manufacturing and human-based model systems. As the NAMs ecosystem grows, our focus remains on building reproducible, high-fidelity human cell systems and the data infrastructure needed to make them useful for discovery, disease modeling, and translational research.
📄 Read more about ORIVA at https://t.co/mwI4Xbtghp
🌐 Learn more about iOB at https://t.co/FCJZoMdidY
The @EU_Commission has taken another significant step toward modernizing biomedical research and safety assessment with its newly released roadmap for phasing out animal testing under the REACH framework.
This initiative outlines a coordinated strategy to accelerate the development, validation, and regulatory acceptance of New Approach Methodologies (NAMs), reinforcing a growing commitment to more human-relevant science across Europe, and joining a worldwide movement now including:
🇺🇲 USA: https://t.co/wpDLrA4680
🇬🇧 UK: https://t.co/QlzdhlOCq9
🇯🇵 Japan: https://t.co/0KFtH7FoJd
🇪🇺 Europe: https://t.co/PYpkbQQkI1
@iOrganBio is helping our partners across the globe navigate this rapidly evolving NAMs landscape by enabling rapid protocol discovery and process development with CellDiscovery™ and scalable cell and organoid manufacturing using CellForge™.
With in vitro model quality and consistency more important than ever, we’re proud to be delivering The Right Cells, Consistently, At Scale.
🌐 Learn more about our technology at https://t.co/2erOow46Yo
#NAMs #Organoids #AnimalTesting #DrugDevelopment #EU
🌴 Get Ready SoCal! We’re just two weeks away from BIO International Convention, and @iOrganBio is excited to be joining the rest of the biotechnology world as we convene in San Diego!
Join iOB CEO @DanielDelubac and COO @karol_jarzabek at BIO to learn more about how iOB is revolutionizing how we design and manufacture cells.
As adoption of New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs) accelerates, one of the major causes of delay is the lack of precision and reliability in the R&D process. Models that better predict human therapeutic response with consistency and reliability are needed in order to maintain the momentum.
At iORGANBIO, we’re leveraging deep transcriptomics and machine learning to control cell fate. Whether unlocking new levels of bioequivalency with CellDiscovery™ or manufacturing cells and organoids with unparalleled reliability using CellForge™, we’re pushing progress forward with The Right Cells, Consistently, At Scale.
🤝 Set up a meeting with the iOB team by emailing [email protected]
🧬 More about #BIO2026 at https://t.co/rPo6xX0O3f
🌐 More about iOB at https://t.co/2erOow46Yo
#NAMs #Organoids #DrugDiscovery #Biopharma
@NCLifeSci
🦓 Progress in the rare disease space is accelerating like never before! Catch the @iOrganBio team next week in Boston at the 2026 World Orphan Drug Congress as we connect with other innovators who are tackling some of the biggest challenges in medicine.
COO @karol_jarzabek and BD Lead Lucas Abbott will be in Boston to share how iOB’s CellDiscovery™ Platform is enabling generation of personalized drug discovery models and powering n-of-one clinical trials for rare diseases, and the CellForge™ Platform is enabling scale-out and scale-up of precision cell manufacturing.
Together with our partners, we’re helping to transform the approach to rare diseases, unlocking new approaches to personalized therapy development and bringing hope to patients and their loved ones with The Right Cells, Consistently, At Scale.
📝 Register for WODC 2026 at https://t.co/6uejavZWbB
🌐 Learn more about iOB’s technology at https://t.co/GkpfmsyGnf
✉️ Explore partnering opportunities by emailing [email protected]
#RareDisease #OrphanDrugs #WODC #PersonalizedMedicine #Nof1 @orphan_drugs@OrphanConf
iOrganBio is excited to share the addition of Zhiping Pang to our Scientific Advisory Board. As one of the world’s foremost experts in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, Dr. Pang has co-authored over 140 publications in top journals.
As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics.
🚀 Welcome aboard Zhiping!
📰 Read the full press release at https://t.co/6BL9jvKhVi
🌐 Learn more about iOB’s technology at https://t.co/FCJZoMdidY
#Neuroscience #Organoids #NAMs #DrugDiscovery #DrugDevelopment
⚡ In a rapidly changing landscape of biological modeling, agility and evidence-based decision-making are essential for new regulatory frameworks.
Earlier this month, the @ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development—with contributions from iOB Co-Founder and Senior Scientific Advisor @ChenShuibing—provided commentary for the @FDA guidance document on NAMs for drug discovery and development. Key highlights included:
🧬 Flexibility in biological complexity and model design
🧩 Fit-for-purpose evaluation beyond comparison to traditional models
⚖️ Clarity of NAM roles within a weight-of-evidence (WoE) framework
🤖 Broader recognition of computational models and AI-integrated NAMs
📐 Right-sizing technical characterization expectations
🔎 Recognizing the unique characteristics of stem cell-derived NAMs
iOrganBio applauds ISSCR for this helpful contribution to the regulatory framework. Each of these points intersect with the challenges we are solving; from customized organoid models that allow investigation of previously unavailable biology, to scalability of consistent and reproducible cell manufacturing, to novel insights now possible through the combination of deep transcriptomics and machine learning.
🗞️ Read the ISSCR release at https://t.co/XQIZwNit1A
🌐 Learn more about the iOB tech platform at https://t.co/FCJZoMdidY
✉️ Reach out to us for partnering opportunities at [email protected]
#NAMs #Organoids #Regulatory #FDA #DrugDevelopment #DrugDiscovery
✍️ Design 🏗️ Build 💥 Test 💡 Learn
These are the core engineering principles that guide the iterative design of everything spanning ballpoint pens to fighter jets. And now we can do the same for cells—completely automated—made possible by advanced robotics and AI.
As part of Boston Tech Week, @iOrganBio Founder and CEO @DanielDelubac will be contributing to a panel discussing the intersection of deep tech and biomedical progress. Joining him for the Heeding Nature's Call: Reading the Body with AI are:
@JohnCapodilupo of @ThroneScience and @WHOOP@LoyConor of @romixbio
Moderated by @drewvolpe of @FirstStarVC, this fireside chat promises to be an engaging update on how deep tech is combining with biotechnology to transform human health. If you’re in Boston for @Techweek_ , you won’t want to miss it!
📝 Register for the event at https://t.co/ICt9Q8tOUg
🤖 Check out the full Boston Tech Week lineup at https://t.co/JcAZQefnm0
🌐 Learn more about iOB at https://t.co/GkpfmsyGnf
#BOSTechWeek #AI #Biotech #Organoids #NAMs
iOrganBio is excited to share the addition of Jessica Owens to our Board of Directors. Bringing with her more than 20 years of experience in the venture capital world, Owens has a proven track record of building companies with impact across technology, life science, and healthcare sectors.
As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics.
🚀 Welcome aboard Jessica!
📰 Read the full press release at https://t.co/FBwjs4kk0J
🌐 Learn more about iOB’s technology at https://t.co/FCJZoMdidY
We’re proud to congratulate @iOrganBio Co-Founder and Senior Scientific Advisor @ChenShuibing on her re-appointment to the @ISSCR Board of Directors.
As highlighted in the ISSCR’s announcement, this recognition reflects Dr. Chen’s continued leadership and influence in advancing stem cell research and regenerative medicine worldwide. Her work sits at the forefront of innovation—bridging fundamental science and translational impact.
We’re honored to have her guidance as part of our team and excited to see her ongoing contributions help shape the future of the field. Congratulations, Shuibing!
📄 Full link here https://t.co/DQQgepnlYw
🌐 Learn more about iOrganBio and our team at https://t.co/2erOow46Yo
🇨🇭The future of cell manufacturing is coming to the heart of Europe! Next week, iOB COO @karol_jarzabek will be heading to Basel, Switzerland for Swiss Biotech Day 2026.
As new approach methodologies gain traction, the need for efficient model development and scalable manufacturing continues to grow. Using the CellDiscovery™ platform’s parallel process development and CellForge™ cell and organoid manufacturing, @iOrganBio is providing our partners with The Right Cells, Consistently, At Scale.
There’s still time to register for Swiss Biotech Day, see the link below.
Event Details:
📆 May 4-5
📍 Basel, CH
🔗 https://t.co/y8aq97Uel4
@SwissBiotech@SBC_Biopharma
#NAMs #Organoids #BioTech #Biopharma
The FDA is replacing animal testing w/ human cell models. To do this, the field needs cell manufacturing that's precise, consistent, and scalable. @iOrganBio is how we'll get there.
✈️ Catch the iOrganBio team at these upcoming events around the globe!
The development of new approach methodologies (NAMs) hinges on the reliability and consistency of the cells that make them up. From organoids to microphysiological systems, adoption of NAMs, iOrganBio is helping partners accelerate process development with the CellDiscovery™ platform and bridge the gap between development and scalable production using CellForge™ manufacturing.
🌐 Find out more about our team and technology by visiting https://t.co/GkpfmsyGnf
✉️ To learn more about working with iOB email [email protected]
#ProcessDevelopment #Biomanufacturing #iPSCs #NAMs #Organoids
@WCM_Innovation@ncbiotech@NCLifeSci@SwissBiotech@SBC_Biopharma
💣 Early clinical development is fraught with risk for drug developers 💥
One of the best ways to mitigate risk of early failures in the clinic is by ensuring that the program’s preclinical data is built on a solid biological foundation, leveraging the latest technical advances from across the biotechnology ecosystem.
🎙️ In this episode of the @PharmTechGroup Drug Digest podcast, iOrganBio CEO @DanielDelubac explains how strategic partnering can both expand access to valuable tools and technologies for drug developers, as well as reduce the time-to-trial cost of advancing a drug development program.
@iOrganBio is proud to be a key player in this partnering ecosystem, accelerating drug discovery through our technology platform components:
🔬 Rapid parallelized in vitro model development with CellDiscovery™
🏭 Scalable and consistent cellular manufacturing with CellForge™
📊 High-resolution state readouts and digitization with CellTelemetry™
When drugmakers identify a need, iOB is there to provide a solid biological foundation to build their work upon, delivering The Right Cells, Consistently, At Scale.
🎧 Catch the full Drug Digest Episode at https://t.co/5r4QdK8QWJ
✉️ Learn more about how iOB’s best-in-class models by emailing [email protected]
🌐 Explore the iOB technology platform at https://t.co/2erOow46Yo
#DrugDevelopment #Organoids #Biopharma #Biomanufacturing